公开(公告)号：US20210070752A1

公开(公告)日：2021-03-11

申请号：US16904890

申请日：2020-06-18

Applicant: Sunesis Pharmaceuticals, Inc. ,  Millennium Pharmaceuticals, Inc.

Inventor： Joseph ARNDT ,  Timothy R. CHAN ,  Kevin GUCKIAN ,  Gnanasambandam KUMARAVEL ,  Wen-Cherng LEE ,  Edward Yin-Shiang LIN ,  Daniel SCOTT ,  Lihong SUN ,  Jermaine THOMAS ,  Kurt VAN VLOTEN ,  Deping WANG ,  Lei ZHANG ,  Daniel ERLANSON

IPC: C07D471/04 ,  C07D213/82 ,  C07D213/85 ,  C07D241/26 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14 ,  C07D409/04 ,  C07D409/14 ,  C07D417/14 ,  C07D473/34 ,  C07D487/04 ,  C07D491/052 ,  C07D519/00 ,  C07D241/28 ,  C07D498/04 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/452 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/497 ,  A61K31/498 ,  A61K31/4985 ,  A61K31/517 ,  A61K31/519 ,  A61K31/53 ,  A61K31/5377 ,  A61K31/5383

Abstract: The present invention provides compounds useful as inhibitors of PDK1. The present invention also provides compositions thereof, and methods of treating PDK1-mediated diseases.

公开(公告)号：US20210032218A1

公开(公告)日：2021-02-04

申请号：US16319506

申请日：2017-01-06

Applicant: Sunesis Pharmaceuticals, Inc. ,  Biogen MA Inc.

Inventor： J. Michael MACPHEE ,  Linda L. NEUMAN

IPC: C07D401/14

Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.

公开(公告)号：US20180316309A1

公开(公告)日：2018-11-01

申请号：US15965741

申请日：2018-04-27

Applicant: Sunesis Pharmaceuticals, Inc.

Inventor： Michelle Arkin ,  Jennifer Hyde ,  Duncan Walker ,  Jasmin Wright

IPC: H02S40/44 ,  F24S50/40 ,  F24S60/30 ,  F24S80/60 ,  C07D471/04 ,  A61K31/555 ,  A61K31/4745 ,  A61K31/44 ,  A61K41/00 ,  A61K9/00 ,  A61K38/18 ,  H01L31/052 ,  A61K38/15 ,  A61K31/337 ,  A61K31/395 ,  A61K31/407 ,  A61K31/4375 ,  A61K31/513 ,  A61K31/519 ,  A61K31/52 ,  A61K31/585 ,  A61K31/704 ,  A61K31/7048 ,  A61K31/7068 ,  A61K33/24 ,  A61K45/06 ,  A61K31/282 ,  H01L31/054 ,  H02S40/38 ,  F24S10/70

CPC classification number: A61K31/4375 ,  A61K9/0019 ,  A61K31/282 ,  A61K31/337 ,  A61K31/395 ,  A61K31/407 ,  A61K31/44 ,  A61K31/4745 ,  A61K31/513 ,  A61K31/519 ,  A61K31/52 ,  A61K31/555 ,  A61K31/585 ,  A61K31/704 ,  A61K31/7048 ,  A61K31/7068 ,  A61K33/24 ,  A61K38/15 ,  A61K38/1816 ,  A61K41/00 ,  A61K45/06 ,  A61K47/12 ,  C07D471/04 ,  F24S10/70 ,  F24S50/40 ,  F24S60/30 ,  F24S80/60 ,  H01L31/0547 ,  H02S40/38 ,  Y02E10/40 ,  Y02E10/52 ,  A61K2300/00

Abstract: The present invention relates to SNS-595 and methods of treating cancer using the same.

公开(公告)号：US10030016B2

公开(公告)日：2018-07-24

申请号：US14966821

申请日：2015-12-11

Applicant: Sunesis Pharmaceuticals, Inc. ,  Millennium Pharmaceuticals, Inc.

Inventor： Joseph Arndt ,  Timothy Chan ,  Kevin Guckian ,  Gnanasambandam Kumaravel ,  Wen-Cherng Lee ,  Edward Yin-Shiang Lin ,  Daniel Scott ,  Lihong Sun ,  Jermaine Thomas ,  Kurt van Vloten ,  Deping Wang ,  Lei Zhang ,  Daniel Erlanson

IPC: C07D471/04 ,  C07D487/04 ,  C07D239/94 ,  C07D241/26 ,  C07D213/82 ,  C07D213/85 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14 ,  C07D409/04 ,  C07D409/14 ,  C07D417/14 ,  C07D473/34 ,  C07D491/052 ,  C07D519/00 ,  C07D241/28 ,  C07D498/04 ,  A61P35/02 ,  A61P35/04 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/452 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/497 ,  A61K31/498 ,  A61K31/4985 ,  A61K31/517 ,  A61K31/519 ,  A61K31/53 ,  A61K31/5377 ,  A61K31/5383

Abstract: The present invention provides compounds useful as inhibitors of PDK1. The present invention also provides compositions thereof, and methods of treating PDK1-mediated diseases.

公开(公告)号：US09839630B2

公开(公告)日：2017-12-12

申请号：US15064498

申请日：2016-03-08

Applicant: Sunesis Pharmaceuticals, Inc.

Inventor： Anantha Sudhakar ,  Tamilarasan Subramani ,  Mohamed Rahuman ,  Ramar Subbiah

IPC: A61K31/4375 ,  C07D471/04 ,  C07D207/14 ,  C07C59/245 ,  C07D207/16 ,  A61K47/10 ,  A61K47/20 ,  A61K9/00 ,  A61K9/08 ,  A61K45/06

CPC classification number: A61K31/4375 ,  A61K9/0019 ,  A61K9/08 ,  A61K45/06 ,  A61K47/10 ,  A61K47/20 ,  C07C59/245 ,  C07D207/16 ,  C07D471/04 ,  Y02P20/55

Abstract: Methods of preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid are disclosed. Also provided are pharmaceutical compositions comprising (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid, and methods of treatment using such compositions.

公开(公告)号：US09724338B2

公开(公告)日：2017-08-08

申请号：US14517535

申请日：2014-10-17

Applicant: SUNESIS PHARMACEUTICALS, INC.

Inventor： Glenn Michelson

IPC: A61K31/4375 ,  A61K31/7068 ,  A61K31/513 ,  A61K45/06 ,  C07D471/04 ,  A61K31/706 ,  A61K38/18 ,  A61K38/19 ,  A61K39/395 ,  A61K39/00

CPC classification number: A61K31/4375 ,  A61K31/513 ,  A61K31/706 ,  A61K31/7068 ,  A61K38/18 ,  A61K38/19 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/54 ,  C07D471/04 ,  A61K2300/00

Abstract: Methods of treating, preventing or managing antecedent hematologic disorders, such as myelodysplastic syndrome, including chronic myelomonocytic leukemia are disclosed. The methods encompass the administration of SNS-595. Also provided are methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. In certain embodiments, the method of treatment comprise administering SNS-595 in combination with cytarabine. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods are also disclosed.

公开(公告)号：US09556177B2

公开(公告)日：2017-01-31

申请号：US14444007

申请日：2014-07-28

Applicant: Millennium Pharmaceuticals, Inc. ,  Sunesis Pharmaceuticals, Inc.

Inventor： Weirong Chen ,  Benjamin Lane ,  Hairuo Peng

IPC: C07D277/20 ,  C07D213/61 ,  C07D487/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D473/00

CPC classification number: C07D417/14 ,  A61K31/506 ,  A61K31/52 ,  A61K31/5377 ,  A61K31/675 ,  A61K45/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D413/14 ,  C07D417/12 ,  C07D471/04 ,  C07D473/00 ,  C07D487/04 ,  C07F9/65583

Abstract: The present disclosure provides compounds having Formula II-vi-a: wherein Cy1, Cy2, and A− are defined as set forth in the specification. These compounds are synthetic intermediates used to prepare inhibitors of Raf protein kinase.

Abstract translation: 本发明提供了可用作Raf蛋白激酶抑制剂的化合物。 本发明还提供了其组合物，以及Raf介导的疾病的治疗方法。

公开(公告)号：US20160317510A1

公开(公告)日：2016-11-03

申请号：US14958103

申请日：2015-12-03

Applicant: Sunesis Pharmaceuticals, Inc.

Inventor： Jeffrey A. SILVERMAN

IPC: A61K31/4375 ,  A61K31/7068 ,  A61K9/00 ,  A61K45/06 ,  A61K33/24 ,  A61K31/555

CPC classification number: A61K31/4375 ,  A61K9/0019 ,  A61K31/282 ,  A61K31/555 ,  A61K31/7068 ,  A61K33/24 ,  A61K45/06 ,  A61K2300/00

Abstract: Methods of treating, preventing or managing cancers are disclosed. The methods encompass the administration of SNS-595 in combination with a second active agent. In certain embodiments, the method of treatment comprise administering SNS-595 in combination with cisplatin, carboplatin, gemcitabine or a combination thereof.

Abstract translation: 公开了治疗，预防或治疗癌症的方法。 所述方法包括与第二活性剂组合施用SNS-595。 在某些实施方案中，治疗方法包括与顺铂，卡铂，吉西他滨或其组合组合施用SNS-595。

公开(公告)号：US20150190380A1

公开(公告)日：2015-07-09

申请号：US14461271

申请日：2014-08-15

Applicant: Sunesis Pharmaceuticals, Inc.

Inventor： Daniel C. Adelman ,  Jeffrey A. Silverman ,  Glenn Michelson ,  Caroline Dame Scatena

IPC: A61K31/4375 ,  C07D417/14

CPC classification number: A61K31/4375 ,  A61K31/513 ,  A61K31/7068 ,  C07D417/14 ,  A61K2300/00

Abstract: Methods of treating, preventing or managing hematologic disorders, such as leukemia are disclosed. The methods encompass the administration of SNS-595. Also provided are methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. In certain embodiments, the method of treatment comprise administering SNS-595 in combination with Ara-C. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods are also disclosed.

Abstract translation: 公开了治疗，预防或治疗血液系统疾病如白血病的方法。 这些方法包括SNS-595的管理。 还提供了使用化合物与化疗，放射治疗，激素治疗，生物治疗或免疫治疗的治疗方法。 在某些实施方案中，治疗方法包括与Ara-C组合施用SNS-595。 还公开了适用于该方法的药物组合物和单一单位剂型。

公开(公告)号：US20150018351A1

公开(公告)日：2015-01-15

申请号：US14328256

申请日：2014-07-10

Applicant: Sunesis Pharmaceuticals, Inc. ,  Millennium Pharmaceuticals, Inc.

Inventor： Kenneth Egnard Lind ,  Kathy Cao ,  Edward Yin-shiang Lin ,  Thinh Ba Nguyen ,  Bradley T. Tangonan ,  Daniel A. Erlanson ,  Kevin Guckian ,  Robert Lowell Simmons ,  Wen-cherng Lee ,  Lihong Sun ,  Stig Hansen ,  Nuzhat Pathan ,  Lei Zhang

IPC: C07D471/04 ,  C07D409/14 ,  C07D401/12 ,  C07D487/04

CPC classification number: C07D471/04 ,  A61K31/4412 ,  A61K31/443 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4985 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5377 ,  C07D211/86 ,  C07D213/64 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D407/14 ,  C07D409/12 ,  C07D409/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D487/04

Abstract: The present invention provides pyridinonyl PDK1 inhibitors and methods of treating cancer using the same.

Abstract translation: 本发明提供吡啶基PDK1抑制剂和使用其制备癌症的方法。